cytarabine has been researched along with nintedanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angenendt, L; Berdel, WE; Butterfass-Bahloul, T; Edemir, S; Gerss, J; Kewitz, T; Knoblauch, N; Krug, U; Mikesch, JH; Müller-Tidow, C; Sauer, T; Schliemann, C; Urban, M; Vehring, K; Wiebe, S | 1 |
| Angenendt, L; Bartscht, T; Berdel, AF; Berdel, WE; Bischoff, M; Butterfass-Bahloul, T; Gerss, J; Hentrich, M; Kewitz, T; Koch, R; Krug, U; Lenz, G; Mikesch, JH; Peceny, R; Schliemann, C; Serve, H; Spiekermann, K; Steffen, B | 1 |
2 trial(s) available for cytarabine and nintedanib
| Article | Year |
|---|---|
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Female; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors | 2016 |
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Indoles; Leukemia, Myeloid, Acute | 2023 |